On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.
According to the pCPA, estimated dollar savings for public drug plans from pCPA negotiations were $4.63 billion ($3.72 billion on brand-name drugs and $0.91 billion on generic drugs), an increase from the estimated $3.89 billion in 2022-2023.
The pCPA also reports there were 41 total negotiations with public drug plans, up by more than 50% from pre-pandemic levels.
The impact report highlights initiatives from 2023-2024, including:
- pCPA Temporary Access Process (pTAP): the pTAP negotiation pathway (see our article) applies to drugs that follow the time-limited reimbursement pathway from Canada’s Drug Agency, ultimately allowing patients to have temporary access to new therapies with conditional approval.
- Three-year pricing initiative for generic drugs: the pricing initiative for generic drugs, the pan-Canadian Tiered Pricing Framework (TPF) (see our article), was renewed and is in effect until 2026.
- New tools: economic insight packages and the negotiation pipeline were introduced to “strengthen negotiations and broaden [the pCPA’s] set of indicators for measuring the impact of the pCPA.”
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
CDA opens consultation on proposed list of drugs to inform development of national formulary
On June 19, 2025, Canada’s Drug Agency (CDA) opened a public consultation on a proposed process for preparing a list of essential prescription drugs and related products.Read More -
Finalized PMPRB Guidelines published
On June 30, 2025, the Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff, which will come into force on January 1, 2026.Read More